Latest glioblastoma multiforme Stories
-- First Observation of Dose Limiting Toxicity Signals VAL-083's Potential Advancement Toward Registration Directed Clinical Trials in Refractory Glioblastoma -- VANCOUVER, British Columbia
Aldoxorubicin Showed 66% Complete or Partial Responses and No Tumor Progression in KS Patients with Excellent Tolerability LOS ANGELES, Jan.
SAN ANTONIO, Jan.
Aldoxorubicin Shows a Complete Response, Tumor Shrinkage, Prolonged Stable Disease, and Favorable Tolerability in Patients LOS ANGELES, Jan.
Doctors Ron Benitez and Yaron Moshel are offering their NJ patients ground -breaking treatments not found anywhere else in the state Morristown, NJ (PRWEB)
BUFFALO, N.Y., Dec.
LOS ANGELES, Dec. 17, 2014 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd.
-- Novel irreversible pan-erbB inhibitor is active against patient-derived GBM xenografts overexpressing EGFR, including the disease-driving EGFRvIII mutation MENLO PARK, Calif., Dec.
BETHESDA, Md., Dec. 11, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S.
- The practice of two or more parties jointly purchasing all or part of a butchered cow and dividing the meat between them.